{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038008","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.074543+00:00","generated_at":"2026-06-04T05:57:19.296177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use","bullets":["Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).","Cash and equivalents $51.1M as of Dec 31, 2023; down from $56.4M year-end 2022.","12 participants enrolled in Phase 2 BESTOW trial of tegoprubart vs tacrolimus in kidney transplant.","Phase 1b data (n=11) showed tegoprubart safe, with eGFR >70 mL/min at all post-90-day time points.","Tegoprubart used in first pig-to-human kidney xenotransplant on March 16, 2024 at Massachusetts General Hospital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038008","json":"https://secwatch.observer/filing/0000950170-24-038008.json","markdown":"https://secwatch.observer/filing/0000950170-24-038008.md","text":"https://secwatch.observer/filing/0000950170-24-038008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/eldn-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:57:19.296177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22e2fcaa3ab8f25097150a8160cbc4320b235bf8","claim":"Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.","evidence_excerpt":"The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"net loss of $40.3 million, or $1.64 per share"},{"label":"EPS","value":"$1.64 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"414690f854f84504fb963a48f452a82b08f7de36","claim":"Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.","evidence_excerpt":"The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"net loss of $9.6 million, or $0.32 per share"},{"label":"EPS","value":"$0.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}